<scp>GPVI</scp> as a Potential New Biomarker for Myelofibrosis Diagnosis
Xavier Hittinger(Nantes Université), Marc Fouassier(Nantes Université), Antoine Babuty(Nantes Université), Patrice Chevallier(Hotel Dieu Hospital), Marion Loirat(Centre Hospitalier Saint-Nazaire), Antoine Bonnet(Centre hospitalier Bretagne Atlantique), Simon Bouzy(Nantes Université), Bruno Villemagne(Centre Hospitalier Départemental Vendée), Raphaël Bourgade(Inserm), Romain Madeuf(Nantes Université), Sophie Vantyghem(Nantes Université), Y. Aiba(Nantes Université), Yannick Le Bris(Centre National de la Recherche Scientifique)
Cited by 0
Related Papers
Prognostic impact of<i>DDX41</i>germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study
|Blood|2022|80
Multicentric Standardized Flow Cytometry Routine Assessment of Patients With Sepsis to Predict Clinical Worsening
|CHEST Journal|2018|63
Deep Learning Methodologies Applied to Digital Pathology in Prostate Cancer: A Systematic Review
|Diagnostics|2023|40
Significance of Measurable Residual Disease in Adult Philadelphia Chromosome–Positive ALL: A GRAAPH-2014 Study
|Journal of Clinical Oncology|2024|39